{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T16:30:29Z","timestamp":1784565029000,"version":"3.55.0"},"reference-count":86,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000008","name":"Health Canada","doi-asserted-by":"publisher","award":["SUAP program"],"award-info":[{"award-number":["SUAP program"]}],"id":[{"id":"10.13039\/501100000008","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Review"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>People with opioid use disorders (OUD) present with high levels of medical and psychosocial vulnerabilities. In recent years, studies have highlighted a shift in demographic and biopsychosocial profiles of people with OUD. In order to support the development of a profile\u2010based approach to care, this study aims to identify different profiles of people with OUD in a sample of patients admitted to a specialised opioid agonist treatment (OAT) facility.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Twenty\u2010three categorical variables (demographic, clinical, indicators of health and social precariousness) were retrieved from a sample of 296 patient charts in a large Montr\u00e9al\u2010based OAT facility (2017<jats:styled-content>\u2013<\/jats:styled-content>2019). Descriptive analyses were followed by a three\u2010step latent class analysis (LCA) to identify different socio\u2010clinical profiles and examine their association with demographic variables.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The LCA revealed three socio\u2010clinical profiles: (i) \u201cpolysubstance use with psychiatric, physical and social vulnerabilities\u201d (37% of the sample); (ii) \u201cheroin use with vulnerabilities to anxiety and depression\u201d (33%); (iii) \u201cpharmaceutical\u2010type opioid use with vulnerabilities to anxiety, depression and chronic pain\u201d (30%). Class 3 individuals were more likely to be aged 45\u2009years and older.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion and Conclusion<\/jats:title><jats:p>While current approaches (such as low\u2010 and regular\u2010threshold services) may be suited for many OUD treatment entrants, there may be a need to improve the continuum of care between mental health, chronic pain, and addiction services for those characterised by the use of pharmaceutical\u2010type opioids, chronic pain and older age. Overall, the results support further exploring profile\u2010based approaches to care, tailored to subgroups of patients with differing needs or abilities.<\/jats:p><\/jats:sec>","DOI":"10.1111\/dar.13634","type":"journal-article","created":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T08:45:03Z","timestamp":1678524303000},"page":"765-777","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["People with opioid use disorders: A taxonomy of treatment entrants to support the development of a <scp>profile\u2010based<\/scp> approach to care"],"prefix":"10.1111","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8980-3664","authenticated-orcid":false,"given":"L\u00e9onie","family":"Archambault","sequence":"first","affiliation":[{"name":"Douglas Research Centre  Montr\u00e9al Canada"},{"name":"Universit\u00e9 de Sherbrooke  Montr\u00e9al Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Bertrand","sequence":"additional","affiliation":[{"name":"Institut Universitaire sur les D\u00e9pendances  Montr\u00e9al Canada"},{"name":"D\u00e9partement des Sciences de la Sant\u00e9 Communautaire Universit\u00e9 de Sherbrooke  Montr\u00e9al Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8474-508X","authenticated-orcid":false,"given":"Didier","family":"Jutras\u2010Aswad","sequence":"additional","affiliation":[{"name":"Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al Research Center  Montr\u00e9al Canada"},{"name":"Department of Psychiatry and Addictology Universit\u00e9 de Montr\u00e9al  Montr\u00e9al Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Monson","sequence":"additional","affiliation":[{"name":"D\u00e9partement des Sciences de la Sant\u00e9 Communautaire Universit\u00e9 de Sherbrooke  Montr\u00e9al Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El Hadj","family":"Tour\u00e9","sequence":"additional","affiliation":[{"name":"Department of Sociology Gaston Berger University  Saint\u2010Louis Senegal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8049-1588","authenticated-orcid":false,"given":"Michel","family":"Perreault","sequence":"additional","affiliation":[{"name":"Douglas Research Centre  Montr\u00e9al Canada"},{"name":"Department of Psychiatry McGill University  Montr\u00e9al Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,3,11]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)33078-2"},{"key":"e_1_2_12_3_1","unstructured":"Government of Canada(2015 [updated 2021 August 12]).Canadian Tobacco Alcohol and Drugs (CTADS): 2015 summary. Available from:https:\/\/www.canada.ca\/en\/health\u2010canada\/services\/canadian\u2010alcohol\u2010drugs\u2010survey\/2015\u2010summary.html. Accessed 3 August 2022"},{"key":"e_1_2_12_4_1","unstructured":"Government of Canada(2019[updated 2021 December 20]).Canadian alcohol and drugs survey (CADS): Summary of results for 2019. Available from:https:\/\/www.canada.ca\/en\/health\u2010canada\/services\/canadian\u2010alcohol\u2010drugs\u2010survey\/2019\u2010summary.html. Accessed 1 August 2022"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-021-00893-z"},{"issue":"13","key":"e_1_2_12_6_1","article-title":"The cost of the opioid epidemic, in context","volume":"25","author":"Kawasaki S","year":"2019","journal-title":"Am J Manag Care"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13011-017-0120-7"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-015-3212-y"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/pme.12430"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2012.08.003"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.58.5.503"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.12.030"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2010.10.001"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000151"},{"key":"e_1_2_12_15_1","first-page":"132","article-title":"Maintaining opioid abstinence long after inpatient treatment with opioid substitution in an addictology hospital unit","volume":"34","author":"Bouab O","year":"2013","journal-title":"Rev Med Brux"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2013.03.009"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.170958"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/HRP.0000000000000075"},{"key":"e_1_2_12_19_1","first-page":"91","volume-title":"The ASAM national practice guideline: for the treatment of opioid use disorder 2020 focused update","author":"American Society of Addiction Medicine (ASAM)","year":"2019"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40429-018-0228-5"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-publhealth-031914-122957"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6450a3"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/dar.12089"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00161-6"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12446"},{"key":"e_1_2_12_26_1","volume-title":"Pain management and the opioid epidemic: balancing societal and individual benefits and risks of prescription opioid use","author":"National Academies of Sciences Engineering and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Committee on Pain Management and Regulatory Strategies to Address Prescription Opioid Abuse","year":"2017"},{"key":"e_1_2_12_27_1","first-page":"463","article-title":"The opioid epidemic: fixing a broken pharmaceutical market","volume":"11","author":"Sarpatwari A","year":"2017","journal-title":"Harv L Poly Rev"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.24095\/hpcdp.38.9.05"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwab129"},{"key":"e_1_2_12_30_1","unstructured":"Government of Canada(2022 [updated 23 June 2022]).Opioid and stimulant related harms in Canada. Available from:https:\/\/health\u2010infobase.canada.ca\/substance\u2010related\u2010harms\/opioids\u2010stimulants. Accessed 3 August 2022."},{"key":"e_1_2_12_31_1","unstructured":"Center for Disease Control and Prevention(2022[updated 11 May 2022]).US overdose deaths in 2021 increased half as much as in 2020\u2013but are still up 15%. Available from:https:\/\/www.cdc.gov\/nchs\/pressroom\/nchs_press_releases\/2022\/202205.htm. Accessed 3 August 2022"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.366"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.3109\/10826084.2013.800112"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/CXA.0000000000000002"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/09595230801956124"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1465-3362.2011.00302.x"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0765-2"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2015.12.021"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/0022042615604345"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1177\/11782218221103581"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005053-198001000-00006"},{"key":"e_1_2_12_42_1","first-page":"26","volume-title":"Validation d'un instrument d'\u00e9valuation de la gravit\u00e9 des probl\u00e8mes reli\u00e9s \u00e0 la consommation de drogues et d'alcool l'indice de gravit\u00e9 de toxicomanie (IGT)","author":"Bergeron J","year":"1992"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.12866"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2018.07.008"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2018.03.012"},{"key":"e_1_2_12_46_1","first-page":"950","volume-title":"Mplus statistical analysis with latent variables: User's guide","author":"Muth\u00e9n LK","year":"1998"},{"key":"e_1_2_12_47_1","volume-title":"Latent class and latent transition analysis: with applications in the social, behavioral, and health sciences","author":"Collins LM","year":"2013"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1177\/0095798420930932"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1037\/tps0000176"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/pan\/mpq025"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1080\/10705511.2014.915181"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1080\/10705510701575396"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2018.05.005"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2012.665729"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000555"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-018-0402-3"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.15288\/jsad.2013.74.605"},{"key":"e_1_2_12_58_1","first-page":"1","article-title":"Exploring foot care conditions for people experiencing homelessness: a community participatory approach","volume":"13","author":"D'Souza MS","year":"2022","journal-title":"J Prim Care Community Health"},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.5845"},{"key":"e_1_2_12_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10900-013-9789-3"},{"key":"e_1_2_12_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14198"},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.1159\/000520185"},{"key":"e_1_2_12_63_1","first-page":"88","volume-title":"Agonistes opio\u00efdes oraux dans le traitement du trouble li\u00e9 \u00e0 l'usage d'opio\u00efdes \u2013 Rapport en soutien au guide d'usage optimal. Written by Alain Pr\u00e9mont","author":"Institut national d'excellence en sant\u00e9 et en services sociaux (INESSS)","year":"2021"},{"key":"e_1_2_12_64_1","volume-title":"Guide d'information et d'orientation pour une offre de traitement par agonistes d'opio\u00efdes injectable au Qu\u00e9bec","author":"Perreault M","year":"2020"},{"key":"e_1_2_12_65_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-022-00592-x"},{"key":"e_1_2_12_66_1","doi-asserted-by":"publisher","DOI":"10.1177\/1049732316679372"},{"key":"e_1_2_12_67_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13011-016-0085-y"},{"key":"e_1_2_12_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2015.04.008"},{"key":"e_1_2_12_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/nin.12275"},{"key":"e_1_2_12_70_1","doi-asserted-by":"publisher","DOI":"10.1055\/a-1298-4508"},{"key":"e_1_2_12_71_1","doi-asserted-by":"publisher","DOI":"10.3109\/10826084.2011.559606"},{"key":"e_1_2_12_72_1","doi-asserted-by":"publisher","DOI":"10.1080\/15504263.2019.1675920"},{"key":"e_1_2_12_73_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2010.10020260"},{"key":"e_1_2_12_74_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADT.0000000000000078"},{"key":"e_1_2_12_75_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540261.2018.1514369"},{"key":"e_1_2_12_76_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2019.1652270"},{"key":"e_1_2_12_77_1","volume-title":"Managing chronic pain in adults with or in recovery from substance use disorders","author":"SAMHSA","year":"2012"},{"key":"e_1_2_12_78_1","unstructured":"Centre for Addiction and Mental Health (CAMH)(2021).Opioid Agonist Therapy: A Synthesis of Canadian Guidelines for Treating Opioid Use Disorder. Available from:https:\/\/www.drugsandalcohol.ie\/34536\/1\/canadian\u2010opioid\u2010use\u2010disorder\u2010guideline\u20102021.pdf"},{"key":"e_1_2_12_79_1","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pny211"},{"key":"e_1_2_12_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2012.08.010"},{"key":"e_1_2_12_81_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000577"},{"key":"e_1_2_12_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2016.11.003"},{"key":"e_1_2_12_83_1","doi-asserted-by":"publisher","DOI":"10.5770\/cgj.23.420"},{"key":"e_1_2_12_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.107574"},{"key":"e_1_2_12_85_1","doi-asserted-by":"publisher","DOI":"10.1037\/ccp0000429"},{"key":"e_1_2_12_86_1","first-page":"552","article-title":"AM last page: quality criteria in qualitative and quantitative research","volume":"88","author":"Frambach JM","year":"2013","journal-title":"Acad Med"},{"key":"e_1_2_12_87_1","first-page":"101","volume-title":"Covid\u201019 and drugs: impact outlook","author":"United Nations Office on Drugs and Crime","year":"2021"}],"container-title":["Drug and Alcohol Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dar.13634","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dar.13634","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dar.13634","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:11:36Z","timestamp":1692663096000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dar.13634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,11]]},"references-count":86,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1111\/dar.13634"],"URL":"https:\/\/doi.org\/10.1111\/dar.13634","archive":["Portico"],"relation":{},"ISSN":["0959-5236","1465-3362"],"issn-type":[{"value":"0959-5236","type":"print"},{"value":"1465-3362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,11]]},"assertion":[{"value":"2022-08-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}